Quantum Net Income From Continuing Ops from 2010 to 2025

QNTM Stock   5.66  1.09  16.15%   
Quantum BioPharma Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to drop to about -22 M. During the period from 2010 to 2025, Quantum BioPharma Net Loss quarterly data regression pattern had sample variance of 13.9 T and median of (28,452,232). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-21 M
Current Value
-22 M
Quarterly Volatility
3.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Quantum BioPharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Quantum BioPharma's main balance sheet or income statement drivers, such as Cost Of Revenue of 1.6 M, Net Interest Income of 949.2 K or Interest Income of 949.5 K, as well as many indicators such as . Quantum financial statements analysis is a perfect complement when working with Quantum BioPharma Valuation or Volatility modules.
  
Check out the analysis of Quantum BioPharma Correlation against competitors.
To learn how to invest in Quantum Stock, please use our How to Invest in Quantum BioPharma guide.

Latest Quantum BioPharma's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Quantum BioPharma over the last few years. It is Quantum BioPharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Quantum BioPharma's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Quantum Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(27,176,586)
Geometric Mean26,905,756
Coefficient Of Variation(13.74)
Mean Deviation2,599,185
Median(28,452,232)
Standard Deviation3,733,724
Sample Variance13.9T
Range15.7M
R-Value0.53
Mean Square Error10.7T
R-Squared0.28
Significance0.03
Slope417,189
Total Sum of Squares209.1T

Quantum Net Income From Continuing Ops History

2025-22 M
2024-21 M
2023-18.2 M
2022-26.7 M
2021-33.9 M

About Quantum BioPharma Financial Statements

Quantum BioPharma investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Quantum Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-21 M-22 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Quantum BioPharma is a strong investment it is important to analyze Quantum BioPharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Quantum BioPharma's future performance. For an informed investment choice regarding Quantum Stock, refer to the following important reports:
Check out the analysis of Quantum BioPharma Correlation against competitors.
To learn how to invest in Quantum Stock, please use our How to Invest in Quantum BioPharma guide.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Quantum BioPharma. If investors know Quantum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Quantum BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(13.00)
Return On Assets
(0.36)
Return On Equity
(0.64)
The market value of Quantum BioPharma is measured differently than its book value, which is the value of Quantum that is recorded on the company's balance sheet. Investors also form their own opinion of Quantum BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Quantum BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Quantum BioPharma's market value can be influenced by many factors that don't directly affect Quantum BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Quantum BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Quantum BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Quantum BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.